Adolore Biotherapeutics, Inc. | WebDisclosure

Basculer en Français

8722	Companies
153353	Keywords
88882	Articles
82425	Press releases

Headlines Articles Press releases Adolore Biotherapeutics, Inc.

Home
Companies
Adolore Biotherapeutics, Inc.

BRIEF

published on 02/04/2025 at 23:05, 4 months 13 days ago

Adolore BioTherapeutics présentera les avancées en matière de thérapie génique au NANS 2025

Adolore BioTherapeutics Douleur Chronique Thérapie Génique Troubles Neurologiques NANS 2025
BRIEF

published on 02/04/2025 at 23:05, 4 months 13 days ago

Adolore BioTherapeutics to Present Gene Therapy Advancements at NANS 2025

Adolore BioTherapeutics Chronic Pain Gene Therapy Neurological Disorders NANS 2025
PRESS RELEASE

published on 02/04/2025 at 23:00, 4 months 13 days ago

Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting
Adolore BioTherapeutics to present CA8* chronic pain therapies and rdHSV delivery technology at 2025 NANS meeting. Company's focus on novel pain treatments highlighted

Adolore BioTherapeutics Neuromodulation CA8* Chronic Pain Therapies RdHSV Delivery Technology NANS
BRIEF

published on 10/02/2024 at 16:05, 8 months 16 days ago

Adolore BioTherapeutics to Present at 18th Annual Pain Therapeutics Summit

Adolore BioTherapeutics Chronic Pain Treatments Opioid Alternatives 18th Annual Pain Therapeutics Summit CA8* Analgesic Peptides
BRIEF

published on 10/02/2024 at 16:05, 8 months 16 days ago

Adolore BioTherapeutics présentera ses travaux au 18e Sommet annuel sur les thérapies contre la douleur

Adolore BioTherapeutics Traitements De La Douleur Chronique Alternatives Aux Opioïdes 18e Sommet Annuel Sur Les Thérapies Contre La Douleur Peptides Analgésiques CA8*
PRESS RELEASE

published on 10/02/2024 at 16:00, 8 months 16 days ago

Adolore BioTherapeutics to Present at 18th Annual Pain Therapeutics Summit
Adolore BioTherapeutics to present innovative opioid-free chronic pain treatments at the 18th Annual Pain Therapeutics Summit in Boston, Ma, based on cutting-edge CA8* analgesic peptides & rdHSV vectors technology

Adolore BioTherapeutics Opioid-free Chronic Pain Treatments CA8 Peptides RdHSV Vectors
BRIEF

published on 09/24/2024 at 14:25, 8 months 24 days ago

Adolore BioTherapeutics présentera son projet lors de l'événement Pitch de BioSparkVA

Adolore BioTherapeutics Douleur Chronique BioSparkVA Roy C. Levitt Thérapie Non Opioïde
BRIEF

published on 09/24/2024 at 14:25, 8 months 24 days ago

Adolore BioTherapeutics to Present at BioSparkVA Pitch Event

Adolore BioTherapeutics Chronic Pain Non-opioid Therapy BioSparkVA Roy C. Levitt
PRESS RELEASE

published on 09/24/2024 at 14:20, 8 months 24 days ago

Adolore BioTherapeutics to Present at BioSparkVA Pitch Event
Adolore BioTherapeutics to present innovative opioid-free chronic pain therapy at BioSpark Pitch Event. Programs for knee osteoarthritis & erythromelalgia in development

Adolore BioTherapeutics Chronic Pain Opioid-free Biotherapeutics Innovative Therapy
BRIEF

published on 07/30/2024 at 14:15, 10 months 19 days ago

Adolore BioTherapeutics Publishes Promising Preclinical Data on Non-Opioid Analgesic Gene Therapy

Adolore BioTherapeutics Chronic Pain Gene Therapy Osteoarthritis Non-opioid Analgesic

Accesswire

Published on 06/18/2025 at 15:15, 4 hours 15 minutes ago

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging
Published on 06/18/2025 at 15:00, 4 hours 30 minutes ago

iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
Published on 06/18/2025 at 14:50, 4 hours 40 minutes ago

Rio Grande Resources Announces Positive Assay Results From its Sampling and Field Campaign at the Winston Gold-Silver Project, New Mexico USA
Published on 06/18/2025 at 14:30, 5 hours ago

Brenmiller Energy Comments on Reverse Share Split Ahead of Expected Near-Term Milestones
Published on 06/18/2025 at 14:30, 5 hours ago

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

View all ACCESSWIRE

EQS Group

Published on 06/18/2025 at 19:16, 13 minutes ago

EQS-Adhoc: Medios adopts public share buyback offer for up to 1 million shares at a price of EUR 12.50
Published on 06/18/2025 at 19:07, 22 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 06/18/2025 at 18:50, 40 minutes ago

EVN and STRABAG signed the transaction agreements for the sale of the international project business
Published on 06/18/2025 at 18:34, 56 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/18/2025 at 18:30, 1 hour ago

Avolta extends retail contract with Grupo Aeroportuario Centro Norte (OMA) in Mexico

Les Echos

Published on 06/18/2025 at 18:00, 1 hour 30 minutes ago

Saint-Gobain enhances its digital construction chemicals platform with the acquisition of Maturix
Published on 06/18/2025 at 18:00, 1 hour 30 minutes ago

Saint-Gobain renforce son offre digitale dans la chimie de la construction avec l’acquisition de Maturix
Published on 06/18/2025 at 17:45, 1 hour 45 minutes ago

COGELEC : Compte rendu de l’Assemblée Générale Mixte du 4 juin 2025.
Published on 06/18/2025 at 17:45, 1 hour 45 minutes ago

Frédéric Chevalier appointed CEO of Lagardère Travel Retail, alongside Dag Rasmussen, effective 1st July, 2025
Published on 06/18/2025 at 17:45, 1 hour 45 minutes ago

Frédéric Chevalier est nommé Directeur Général de Lagardère Travel Retail aux côtés de Dag Rasmussen, à compter du 1er juillet 2025.

View all LES ECHOS COMFI WIRE